AMPH — Amphastar Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1297184 ·
Last close
$19.98
Market Cap
$849.91M
52W High
$22.65
52W Low
$16.65
ADV30
442,315
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 183,903,000 | 93,470,000 | 39,729,000 | 30,348,000 | 1,743,766,000 | 223,614,000 | 975,609,000 |
| Mar 2026 | 171,171,000 | 70,322,000 | 13,630,000 | 6,420,000 | 1,648,162,000 | 170,939,000 | 874,771,000 |
| Dec 2025 | 183,105,000 | 85,670,000 | 35,606,000 | 24,429,000 | 1,629,299,000 | 170,177,000 | 840,494,000 |
| Sep 2025 | 191,840,000 | 98,646,000 | 25,320,000 | 17,350,000 | 1,666,222,000 | 216,265,000 | 889,476,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$168,878,000
Investing CF
$-97,546,000
Financing CF
$-83,129,000
CapEx
$-35,942,000
Dividends Paid
—
Buybacks
$-94,078,000
EPS Diluted TTM
$1.66
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$673,301,000
Inventory
$170,194,000
Receivables
$157,453,000
ST Investments
$121,012,000
EBIT TTM
$128,562,000
Pretax Income TTM
$102,814,000
Interest Exp TTM
$25,748,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$730,019,008
EBITDA
$194,514,000
Free Cash Flow
$230,095,872
Enterprise Value
$1,248,107,136
Total Cash
$290,123,008
Total Debt
$688,321,984
Shares Out
42,537,944
Trailing EPS
$1.69
Book Value
$18.06
ROE
10.3%
ROA
5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 719,887,000 | 140,403,000 | 98,094,000 | 1,629,299,000 | 840,494,000 | — | 156,115,000 |
| Dec 2024 | 731,967,000 | 205,419,000 | 159,519,000 | 1,577,470,000 | 845,172,000 | — | 213,386,000 |
| Dec 2023 | 644,395,000 | 196,987,000 | 137,545,000 | 1,512,912,000 | 873,491,000 | — | 183,503,000 |
| Dec 2022 | 498,987,000 | 107,497,000 | 91,386,000 | 741,987,000 | 213,329,000 | — | 89,181,000 |
TTM Snapshot
Revenues TTM
$604,097,000
NetIncome TTM
$135,073,000
OpCashFlow TTM
$0
Assets (Latest)
$1,577,470,000
Forward EPS
$3.05
Max Pain — expiry 2026-08-21
max pain strike: $20.00 · spot: $20.18 · call oi: 1,571 · put oi: 17
Expected Move to 2026-08-21:
±$2.50
(12.39%) —
implied range
$17.68 –
$22.68
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IVEVF | Inventiva S.A. | $848.03M | $3.59 | — |
| ACRS | Aclaris Therapeutics, Inc. | $859.64M | $5.84 | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $861.16M | $5.78 | — |
| PHAR | Pharming Group N.V. | $837.31M | $11.83 | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $833.55M | $25.70 | — |
News headlines (Yahoo Finance, 1h cache)
AMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive Results
2026-08-11 08:13 · Yahoo
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
2026-08-06 23:30 · Yahoo
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
2026-08-06 23:10 · Yahoo
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
2026-08-06 23:03 · Yahoo
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026
2026-08-06 21:11 · Yahoo
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
2026-08-06 20:05 · Yahoo
1 Value Stock to Own for Decades and 2 Facing Challenges
2026-08-03 18:29 · Yahoo
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
2026-07-30 14:00 · Yahoo
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
2026-07-29 10:00 · Yahoo
3 Reasons AMPH is Risky and 1 Stock to Buy Instead
2026-07-29 06:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.